Demographics and baseline disease activity measures for all patients, as well as compared across number of previous b/tsDMARDs
| All patients (n=1860) | b/tsDMARD-naïve patients (n=414) | 1 prior b/tsDMARD (n=448) | 2 or more prior b/tsDMARDs (n=998) | P value* | ||
|---|---|---|---|---|---|---|
| Age (years), mean (SD), median (IQR), n available | 47.1 (11.9), 47 (38–56) n=1860 | 45.4 (11.9), 45 (36–54) n=414 | 46.8 (11.9), 46 (38–56) n=448 | 48.0 (11.8), 48 (39–57) n=998 | 0.001 | |
| Men, % n available | 55.5% n=1860 | 68.1% n=414 | 57.8% n=448 | 49.2% n=998 | <0.001 | |
| Years since diagnosis, mean (SD), median (IQR) n available | 9.9 (9.0), 7 (3–14) n=1560 | 8.1 (9.0), 5 (1–12) n=396 | 10.0 (9.4), 7 (3–15) n=403 | 10.7 (8.6), 8 (4–15) n=761 | <0.001 | |
| Current smokers, %, n available | 24.6% n=1696 | 26.8% n=380 | 25.4% n=410 | 23.4% n=906 | 0.40 | |
| Patient’s global assessment (0–100), median (IQR), n available | 70 (50–81) n=1324 | 80 (60–90) n=292 | 64 (50–80) n=310 | 70 (50–82) n=722 | <0.001 | |
| Physician’s global assessment (0–100), median (IQR), n available | 45 (25–63) n=780 | 64 (43–78) n=175 | 45 (22–60) n=156 | 40 (20–58) n=449 | <0.001 | |
| Health Assessment Questionnaire (0–3), mean (SD), median (IQR), n available | 1.1 (0.6), 1.1 (0.6–1.5) n=843 | 1.1 (0.6), 1.1 (0.8–1.6) n=187 | 1.1 (0.6), 1.1 (0.6–1.5) n=162 | 1.1 (0.6), 1.0 (0.6–1.5) n=494 | 0.76 | |
| Body mass index (kg/m2), median (IQR), n available | 27 (24–31) n=1058 | 27 (24–30) n=333 | 27 (24–31) n=274 | 27 (23–31) n=451 | 0.97 | |
| C reactive protein (mg/L), median (IQR), n available | 8 (3–25) n=1454 | 15 (5–31) n=337 | 7 (3–25) n=341 | 6 (2–22) n=776 | <0.001 | |
| Erythrocyte sedimentation rate (mm/h), median (IQR), n available | 22 (9–44) n=1143 | 30 (14–44) n=296 | 24 (8–45) n=286 | 18 (8–42) n=561 | <0.001 | |
| Pain (0–100), median (IQR), n available | 70 (50–81) n=1299 | 80 (65–90) n=288 | 65 (49–80) n=299 | 70 (50–80) n=712 | <0.001 | |
| Fatigue (0–100), median (IQR), n available | 70 (50–82) n=1190 | 77 (60–90) n=266 | 65 (45–80) n=279 | 70 (50–84) n=645 | <0.001 | |
| BASDAI, median (IQR), mean (SD), n available | 6.2 (4.6–7.6), 6.0 (2.2) n=1444 | 6.8 (5.2–8.0), 6.4 (2.1) n=371 | 5.9 (4.2–7.2), 5.6 (2.3) n=349 | 6.1 (4.4–7.6), 5.9 (2.2) n=724 | <0.001 | |
| BASFI, median (IQR), n available | 5.5 (3.2–7.3) n=872 | 6.1 (3.2–7.6) n=191 | 4.8 (2.8–6.8) n=169 | 5.5 (3.3–7.2) n=512 | 0.04 | |
| ASDAS, median (IQR), n available | 3.6 (2.9–4.3) n=1241 | 4.2 (3.5–4.8) n=292 | 3.5 (2.7–4.2) n=297 | 3.5 (2.8–4.2) n=652 | <0.001 | |
| First b/tsDMARD treatment | Adalimumab, n (%) | 397 (27.5) | NA | 125 (27.9) | 272 (27.3) | 0.84 |
| Certolizumab, n (%) | 76 (5.3) | NA | 27 (6.0) | 49 (4.9) | 0.45 | |
| Etanercept, n (%) | 362 (25.0) | NA | 115 (25.7) | 247 (24.7) | 0.76 | |
| Golimumab, n (%) | 170 (11.8) | NA | 75 (16.7) | 95 (9.5) | <0.001 | |
| Infliximab, n (%) | 357 (24.7) | NA | 82 (18.3) | 275 (27.6) | <0.001 | |
| Other, n (%) | 8 (0.6) | NA | 4 (0.9) | 4 (0.4) | 0.21 | |
| Missing, n (%) | 76 (5.3) | NA | 20 (4.5) | 56 (5.6) | 0.40 | |
| n available | n=1446 | NA | n=448 | n=998 | ||
*Comparisons between b/tsDMARD-naïve, 1 prior and ≥2 prior b/tsDMARD-treated patients were performed with χ² test, ANOVA or Kruskal-Wallis, as appropriate.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; b/tsDMARD, biologic/targeted synthetic disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug.